Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy

Blood Cells Mol Dis. 2018 Feb:68:180-184. doi: 10.1016/j.bcmd.2017.01.007. Epub 2017 Jan 16.

¹ Ege University, Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, Turkey. Electronic address: ebru.canda@gmail.com.
² Ege University, Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, Turkey. Electronic address: drmelisdemir@gmail.com.
³ Ege University, Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, Turkey. Electronic address: mehtapsanlilar@hotmail.com.
⁴ Ege University, Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, Turkey. Electronic address: semakalkan@hotmail.com.
⁵ Ege University, Faculty of Medicine, Department of Biochemistry, Turkey. Electronic address: eser.sozmen@ege.edu.tr.
⁶ Ege University, Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, Turkey. Electronic address: mahmut.coker@ege.edu.tr.

No abstract available

Keywords: Gaucher; Imiglucerase; Substrate reduction therapy.

MeSH terms